589 million adults were living with diabetes in 2024, and 81% of them in low- and middle-income countries. That figure is projected to reach 853 million by 2050, with 43% of current cases still undiagnosed.
284 of these 344 lines are oral solids, including empagliflozin and dapagliflozin across 22 presentations and sacubitril with valsartan in all three strengths.
Range depth
11 empagliflozin and 11 dapagliflozin presentations.
Sacubitril and valsartan across all three strengths.
Rivaroxaban in 7 presentations, apixaban in 4.
22 telmisartan presentations, including triple combinations.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.